USFDA inspection at Enzene Biosciences Pune facility ends with 6 observations

Regulatory & Legal View source PDF Explain this filing

ALKEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.4%Reaction day

₹5400.00

prior close

₹5485.00

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.4%+1.0% vs market

Pharmaceuticals peers, median of 154sector-0.5%+1.9% vs sector

On the reaction day the stock moved 1.0 pts more than Nifty Midcap 150 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.1

15m

+0.0

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.4+0.4+1.0-0.5+1.9

Next day

+1.1+0.7+0.4-0.0+1.2

+1.1+1.3-0.1+0.0+1.1

-0.3-0.3+0.0-0.9+0.6

-0.1+0.2-0.2-1.5+1.4

+1.6-0.0+1.6-1.2+2.8

+4.6+0.3+4.2-2.1+6.7

15d

+3.7-3.7+7.4-5.0+8.7

-2.0-7.9+5.8-7.4+5.4

+3.0-0.5+3.4-0.3+3.3

+1.3+1.5-0.1+2.7-1.4

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

USFDA completed a Pre-Approval Inspection on 13 Feb 2026 at Enzene Biosciences, a subsidiary of Alkem Laboratories, at its Chakan Pune facility. The inspection closed with a Form 483 carrying 6 procedural observations. Importantly, zero observations were related to data integrity. Enzene is preparing its response to the USFDA within the required timeline and has started corrective and preventive actions.

Likely market impact

Generally neutral. Six procedural observations are common; clean data integrity record is a positive signal for regulatory credibility.